CYBIN INC.
HELP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HELP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HELP
Cybin Inc., now operating as Helus Pharma (NASDAQ: HELP), is a clinical-stage biopharmaceutical company developing psychedelic-based therapies for psychiatric disorders, with lead candidate HLP003 in Phase 3 trials for major depressive disorder.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2025.
Tracking 4 clinical trials · 3 catalysts for CYBIN INC..
Cybin Inc., now operating as Helus Pharma (NASDAQ: HELP), is a clinical-stage biopharmaceutical company developing psychedelic-based therapies for psychiatric disorders, with lead candidate HLP003 in Phase 3 trials for major depressive disorder.
- Cybin rebranded to Helus Pharma and relisted on Nasdaq under ticker HELP in January 2026 [news · 2026-01-11].
- Lead candidate HLP003 has FDA Breakthrough Therapy designation for major depressive disorder and is in Phase 3 trials [news · 2026-01-11].
- Cash and equivalents were $135.0M as of 2025-03-31 [sec].
- Shareholders' equity was $48.2M as of 2025-03-31 [sec].
- The company filed a $100,000,000 at-the-market follow-on equity offering of common shares [news · 2026-01-11].
What works
- HLP003 has FDA Breakthrough Therapy designation, which may expedite development and review [news · 2026-01-11].
- The company has a cash position of $135.0M as of 2025-03-31, providing runway for ongoing Phase 3 trials [sec].
- Jefferies initiated coverage with a Buy rating, highlighting psilocybin therapies as key growth drivers [news · 2026-02-19].
What to weigh
- The company has an accumulated deficit and is not yet profitable, typical for clinical-stage biotechs [sec].
- Phase 3 topline results for HLP003 are not expected until September 2026 at the earliest, creating a long wait for potential catalysts [catalyst].
- The company faces competition from established players like Pfizer and Eli Lilly in the major depressive disorder space [competitor_trial].
- The stock dropped 9.1% after the rebranding and Nasdaq relisting, suggesting market skepticism [news · 2026-01-11].
From the filings
Quoted directly from source documents.
Cybin rebranded to Helus Pharma and relisted on Nasdaq.
“Cybin Inc., now operating as Helus Pharma, has rebranded and moved its U.S. listing from NYSE American to Nasdaq under the ticker HELP”
News · January 11, 2026
HLP003 has FDA Breakthrough Therapy designation.
“FDA Breakthrough Therapy-designated Phase 3 candidate HLP003 for major depressive disorder”
News · January 11, 2026
Catalyst timeline
- 2026-09-01 · Phase3_Topline — Topline results from a Phase III placebo-controlled trial of CYB003 (HLP003) for major depressive disorder, measuring MADRS endpoint.
- 2027-05-08 · Phase3_Topline — Topline results from a second Phase III study comparing HLP003 to control in major depressive disorder, measuring MADRS.
- 2028-03-15 · Phase3_Topline — Topline results from a long-term extension trial of HLP003 assessing safety and optional additional doses.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Phase 3 trials for HLP003 may fail to meet endpoints, leading to significant stock decline [catalyst].
- Cash burn and dilution — With $135M cash but no revenue, the company may need further financing, diluting shareholders [sec].
- Competitive landscape — Major depressive disorder is crowded with competitors like Pfizer, Eli Lilly, and Biohaven [competitor_trial].
- Regulatory and market adoption — Psychedelic therapies face regulatory hurdles and stigma, potentially limiting commercial uptake [news].
What to watch
- Phase 3 topline results for HLP003 expected September 2026 [catalyst].
- Additional Phase 3 readouts for HLP003 in May 2027 and March 2028 [catalyst].
- Progress of HLP004 for generalized anxiety disorder [news · 2026-01-11].
- Any updates on the at-the-market equity offering and cash runway [news · 2026-01-11].
Sources: Catalysts · Competitor trials · News · Generated August 20, 2026 · How we verify sources →
Run CYBIN INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CYBIN INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.09
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~2d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$92.0M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 3,832,843 | $18.4M |
| millennium management llc | 2,415,841 | $11.6M |
| acorn capital advisors, llc | 1,540,266 | $7.4M |
| eventide asset management, llc | 1,410,815 | $6.8M |
| deep track capital, lp | 1,313,137 | $6.3M |
| morgan stanley | 1,025,318 | $4.9M |
| sphera funds management ltd. | 987,090 | $4.7M |
| citadel advisors llc | 915,647 | $4.4M |
| adage capital partners gp, l.l.c. | 700,000 | $3.4M |
| dcf advisers, llc | 691,988 | $3.3M |
Showing top 10 of 79 institutional holders of CYBIN INC.. Open the full 13F history after sign-in.
Frequently asked questions
What is the AI investment thesis for CYBIN INC.?
Cybin Inc., now operating as Helus Pharma (NASDAQ: HELP), is a clinical-stage biopharmaceutical company developing psychedelic-based therapies for psychiatric disorders, with lead candidate HLP003 in Phase 3 trials for major depressive disorder.
What is CYBIN INC.'s next catalyst?
CYBIN INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Co" — expected September 1, 2026.
Who is the CEO of CYBIN INC.?
Mr. Michael I. Halstead J.D. is the chief executive officer of CYBIN INC. (HELP).
Where is CYBIN INC. headquartered?
CYBIN INC. (HELP) is headquartered in Toronto, ON, Canada.
What therapeutic areas does CYBIN INC. focus on?
CYBIN INC. develops therapies across Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.